---
title: "Granules India shares in focus after arm gets VAI status post USFDA inspection"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281284912.md"
description: "Granules India shares are in focus after its subsidiary, Granules Life Sciences, received a Voluntary Action Indicated (VAI) status from the USFDA following an inspection of its Telangana facility. The inspection, conducted in December 2025, resulted in no regulatory action. Earlier, Granules Consumer Health LLC also received a No Action Indicated (NAI) status from the USFDA. The share price has increased over 25% in the last nine months, closing at Rs 621.15, down 0.34%. The stock is currently trading below its 52-week high of Rs 640.00 and above its low of Rs 412.05, with a market cap of Rs 15,391.91 crore."
datetime: "2026-04-01T01:53:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281284912.md)
  - [en](https://longbridge.com/en/news/281284912.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281284912.md)
generator: "portal-rs"
---

# Granules India shares in focus after arm gets VAI status post USFDA inspection

Granules India shares will be in focus on April 1 after its wholly owned subsidiary, Granules Life Sciences, received a Voluntary Action Indicated (VAI) classification following an inspection by the United States Food and Drug Administration.

The inspection of its manufacturing facility in Shamirpet, Telangana, was conducted between December 15 and 19, 2025, covering current Good Manufacturing Practice (cGMP) and pre-approval inspection (PAI) for oral solid dosage operations.

The Establishment Inspection Report (EIR) has been issued, and the inspection has now been closed with no regulatory action recommended.

**Catch all the market action on our live blog**

Earlier in the month of March, its US step-down subsidiary, Granules Consumer Health LLC (a wholly-owned subsidiary of Granules Pharmaceuticals, Inc.), has received an Establishment Inspection Report (EIR) with a No Action Indicated (NAI) status from the USFDA following an inspection at its Manassas, Virginia packaging facility conducted between December 1 and 3, 2025.

The share price jumped more than 25 percent in the last nine months.

In the previous trading session, the share closed at Rs 621.15, down Rs 2.10, or 0.34 percent.

The share touched a 52-week high of Rs 640.00 and a 52-week low of Rs 412.05 on 25 March, 2026 and 07 April, 2025, respectively.

Currently, the stock is trading 2.95 percent below its 52-week high and 50.75 percent above its 52-week low.

The market capitalisation of the company stands at Rs 15,391.91 crore.

### Related Stocks

- [GRAN.US](https://longbridge.com/en/quote/GRAN.US.md)
- [NDIA.US](https://longbridge.com/en/quote/NDIA.US.md)
- [INDA.US](https://longbridge.com/en/quote/INDA.US.md)

## Related News & Research

- [Sandisk Stock Is Falling Thursday: What's Going On?](https://longbridge.com/en/news/301982790.md)
- [Peter Schiff Warns Trump’s ‘Booming’ Stock Market Boast Is a Mirage: 479 Stocks Hit 52-Week Lows on Wednesday, While Only 60 Set Highs](https://longbridge.com/en/news/301958076.md)
- [Anthropic's Q3 revenue surges 45% to nearly $17 billion](https://longbridge.com/en/news/301892950.md)
- [Why Is Rocket Lab Stock Plunging in Premarket Today? What This Top Analyst Sees Next](https://longbridge.com/en/news/301962657.md)
- [Fantastic News for Marvell Stock Investors](https://longbridge.com/en/news/302002479.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**